SHAILYNSEShaily Engineering Plastics Limited· Consumer DurablesHighNeutral
Announced Tue, 19 May, 2026 · 18:18 IST

Shaily Engineering Plastics Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026.

Revenue Growth 20pctPat Growth 25pctResults View source PDFExplain this filing

SHAILY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.2%Reaction day
₹2630.00
prior close
₹2403.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%+2.6% vs market
Plastic Products - Consumer peers, median of 7sector+1.4%+1.9% vs sector

On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250 and 1.9 pts more than its Plastic Products - Consumer peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.4
10m
+5.4
15m
+13.4
30m
+12.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.2+0.6+2.6+1.4+1.9
Next day
+4.3+1.7+2.6+2.5+1.8
2d
+2.2+1.8+0.4+1.8+0.4
3d
+4.6+3.4+1.2+4.4+0.1
4d
+2.0+4.1-2.2+2.3-0.3
5d
+1.3+4.1-2.8+4.0-2.7
1w
+19.4+2.3+17.1+2.0+17.4
15d
+11.2+1.8+9.4+4.9+6.2
1m
+5.1+10.8-5.6+7.2-2.1
2m
+9.2+10.3-1.1+13.5-4.3
3m
+27.5+14.9+12.5+4.5+22.9
UpDownMarket · Nifty Microcap 250Sector · Plastic Products - Consumer peers, median of 7Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shaily Engineering Plastics reported strong FY26 results with standalone revenue of Rs. 92,120 lakhs, up 21.5% from Rs. 75,812 lakhs in FY25. Standalone net profit surged 127.5% to Rs. 16,132 lakhs from Rs. 7,091 lakhs. Consolidated revenue grew 25.9% to Rs. 99,067 lakhs with PAT at Rs. 16,991 lakhs, up 82.5%. The board recommended a dividend of Rs. 3 per share (150%). Key appointments include Mr. Joe Kam as COO Healthcare and new internal and cost auditors. The company passed an enabling resolution to raise up to Rs. 500 crores to fund diversification into semiconductor trays (via a Korean firm supply agreement), consumer electronics, and healthcare drug delivery devices. B S R & Co issued an unmodified (clean) audit opinion on both standalone and consolidated results.

Likely market impact

Strong operational performance with over 20% revenue growth and 80%+ PAT growth signals robust execution. The Rs. 500 crore fund raise authorization indicates significant capital investment planned for diversification into high-growth sectors like semiconductors. Clean audit opinion removes any concerns about financial reporting quality.